In concordance with this idea, a recent study has shown that genetic ablation/deletion or pharmacological inhibition of EZH2 triggered feedback activation of NF-κB via the EZH2-SOX9-TNFRSF11A signalling axis in prostate cancer cells. Here, EZH2 is linked to prostate carcinoma.